Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
May 2016

Flibanserin (Addyi): Data and Opinion
Further research is required to determine whether the modest benefits from flibanserin (Addyi) for women with acquired generalized hypoactive sexual desire disorder outweigh its risks.

Varenicline in Schizophrenia
A recent study of varenicline (Chantix) in patients with schizophrenia found that, compared with placebo, it reduced smoking without increasing psychiatric symptoms and was well tolerated but did not improve cognition.

New Treatment Approaches for Bipolar Depression
Recent studies of treatments for bipolar depression report that lamotrigine (Lamictal and others) added to quetiapine (Seroquel and others) improves depressive symptoms; folic acid may reduce the effectiveness of lamotrigine; and agomelatine is not efficacious in this population.

In Brief
Primary Care Physicians Use Management Care Processes Less for Depression than for Other Chronic Illnesses: Antipsychotic-Treated Patients with Schizophrenia Experience No Benefits from Adjunctive Oxytocin

About the BTP Newsletter

Our subscribers say BTP is…

"Very relevant, practical, and thought-provoking."

"About the only thing left without drug ads...objective and balanced."

"Succinct, readable, clear, timely and relevant!"

"Well written and scientifically sound."

Originating at the Massachusetts General Hospital and Harvard Medical School, Biological Therapies in Psychiatry has been a trusted resource for physicians for over 30 years. Described as "influential" by the Atlantic Monthly, this concise, four-page, monthly newsletter provides up-to-date information about the rapidly expanding field of psychotropic medications and other biological treatments for mental disorders.

From his perspective as an editor, teacher, investigator, and clinician, Alan J. Gelenberg, M.D., reviews the widespread literatures of science and clinical practice. Dr. Gelenberg distills the material most relevant for a busy practitioner and presents it each month with a balance of scientific curiosity, healthy skepticism, and clinical experience.

Dr. Gelenberg is Professor and Interim Chair of Psychiatry at Penn State, Hershey. Since 1987, Dr. Gelenberg has been Editor-in-Chief of the Journal of Clinical Psychiatry, and he recently chaired the workgroup that revised the American Psychiatric Association's major depressive disorder guidelines. Dr. Gelenberg has been on the faculty of Harvard Medical School, MIT, and the University of Arizona and has written numerous scientific articles and book chapters on mood disorders, depression, and schizophrenia. He is listed in the Best Doctors in America and America's Top Doctors and received the 1997 Exemplary Psychiatrist Award of the National Alliance for the Mentally Ill.

We offer both print and online subscriptions. Our web site provides subscribers with 24-hour access to archives as well as current issues. In addition, Continuing Medical Education credit is available for reading BTP. You can earn up to 12.0 hours in category 1 credit by answering questions in the December issue about topics covered during the year.